Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

Mateja Horvat; Barbara Novakovic

doi:10.2478/v10019-010-0044-6

.blurhash-client-img { display: none !important; }

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

Radiology and Oncology

Volume 44 (2010): Issue 4 (December 2010)

By: Mateja Horvat and Barbara Novakovic

Open Access

|Oct 2010

Primic Žakelj M, Bračko M, Hočevar M, Pompe-Kirn V, Strojan P, Zadnik V, Zakotnik B and Žagar T, editors.Ljubljana: Institute of Oncology Ljubljana, Cancer registry of Republic of Slovenia; 2009.
Search in Google Scholar
Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia.2006;: 791-820.
Open DOI Search in Google Scholar
Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.2008;: 237-50.
Open DOI Search in Google Scholar
Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.2004;: 2654-61.
Open DOI Search in Google Scholar
Nickenig C, D reyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.2006;: 1014-22.
Open DOI Search in Google Scholar
Sebban C, Mo unier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).2006;: 2540 Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma.2006;: 1590-6.
Open DOI Search in Google Scholar
Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma.2006;: 1590-6.
Open DOI Search in Google Scholar
Huic D, Mutvar A, Kinda-Basic S, Aurer I, Ciglar M, Grosev D, et al. Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study.2009;: 258-63.
Open DOI Search in Google Scholar
Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, et al. Longterm follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - a study from the Groupe d'Etude des Lymphomes de l'Adulte.2010;: 822-9.
Open DOI Search in Google Scholar
Samardziski M, Zafiroski G, Tolevska C, Kalicanin-Markovska M, Doncovska D, Anevska V, et al. Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results.2009;: 187-94.
Search in Google Scholar
Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.2008;: 213-23.
Open DOI Search in Google Scholar
Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.2008;: 4824-31.
Open DOI Search in Google Scholar
Jezeršek Novaković B, Benigar A. Treatment of NonHodgkin's lymphomas with rituximab in Slovene patients.2010;: 167-76.
Open DOI Search in Google Scholar
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.2003;: 7359-68.
Open DOI Search in Google Scholar
Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.2005;: 1417-23.
Open DOI Search in Google Scholar
Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.2005;: 3725-32.
Open DOI Search in Google Scholar
Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.2007;: 1986-92.
Open DOI Search in Google Scholar
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.2005;: 4117-26.
Open DOI Search in Google Scholar
Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.2006;: 3121-7.
Open DOI Search in Google Scholar
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.2006;: 379-91.
Open DOI Search in Google Scholar